Preoperative chemotherapy for bladder cancer: A standard waits to be optimally deployed

Cancer

Volumn 118, Issue 1, 2012, Pages 8-11

  Sonpavde, Guru ^a,b   Shariat, Shahrokh F ^c  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; SUNITINIB; VINBLASTINE;

ADJUVANT THERAPY; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CYSTECTOMY; DOSE RESPONSE; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; URINARY BLADDER NEOPLASMS;

EID: 83855162896     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26239     Document Type: Review

References (18)

1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866. (Pubitemid 37025405)
2. Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010; 16: 4461-4467.
3. Feifer A, Taylor JM, Shouery M, et al. B.C.A.N. Muscle-Invasive Bladder Cancer Quality of Care Consortium. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder [abstract]. J Clin Oncol. 2011; 29 (suppl 7). Abstract 240.
4. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006; 107: 506-513. (Pubitemid 44107210)
5. Sonpavde G, Khan MM, Svatek RS, et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy [published online ahead of print November 19, 2010]. BJU Int. 2010.
6. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009; 55: 177-185.
7. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 4005-4013. (Pubitemid 32976686)
8. Scosyrev E, Messing E, van Wijngaarden E, et al. Neoadjuvant gemcitabine-cisplatin for locally advanced urothelial carcinoma of the bladder. Cancer. 2011; 118: 72-81.
9. Herr HW, Donat SM, Bajorin DF,. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2. 2001; 165: 811-814. (Pubitemid 32156284)
10. Kassouf W, Agarwal PK, Grossman HB, et al. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urol. 2009; 73: 147-152.
11. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009; 115: 4104-4109.
12. DeVere White RW, Lara PN Jr, Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009; 281: 2476-2480; discussion 2480-2481.
13. Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008; 113: 2471-2477.
14. Hussain SA, Stocken DD, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004; 91: 844-849. (Pubitemid 39273773)
15. Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010; 116: 3127-3134.
16. Sonpavde G, Khan MM, Lerner SP, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011; 185: 456-461.
17. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007; 18: 522-528. (Pubitemid 46359633)
18. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 2009; 69: 8302-8309.